Disease-Targeted Treatment Improves Cognitive Function in Patients with Precapillary Pulmonary Hypertension

Abstract

Background: Patients with pulmonary hypertension (PH) may suffer from cognitive deficits that potentially relate to reduced oxygen delivery and cerebral tissue oxygenation (CTO). Objective: To evaluate the hypothesis that cognitive function improves with therapy, along with improved CTO. Methods: Twenty incident patients with arterial or chronic thromboembolic PH had CTO monitoring by near-infrared spectroscopy during diagnostic right heart catheterization. Cognitive tests [Trail Making Tests (TMTs), Victoria Stroop tests and the Five-Point Test (5PT)], the 6-min walk distance (6MWD) test, New York Heart Association (NYHA) class and health-related quality of life (HRQoL) were assessed and repeated after 3 months of disease-targeted medication. Results: At baseline, 45% of PH patients had cognitive deficits. At 3 months, the patients had improved on the TMT A and the Stroop 2 test [37 s (27; 55) versus 30 s (24; 42), p < 0.05, and 18 s (16; 22) versus 16 s (15; 20), p < 0.01], whereas CTO remained unchanged. Arterial oxygen saturation, NYHA class, 6MWD and HRQoL had also improved. Baseline CTO was the strongest predictor of cognitive function, even in multivariate analysis including age, 6MWD and HRQoL. Improvements in cognitive function were not associated with changes in CTO. Conclusions: In patients with PH, 3 months of disease-targeted medication resulted in better cognitive function. Although CTO was the strongest predictor of cognitive function at baseline, it did not change during target therapy. The results of this pilot study should be confirmed in an adequately powered controlled trial.

Brain Structural Changes in Patients with Pulmonary Arterial Hypertension

“…Guillevin et al reported various social challenges in the PAH group, such as difficulties in maintaining social relationships, significant financial problems, as well as mood lability 31 . We found significant cognitive impairment in PAH patients, especially in delayed recall, consistent with previous studies 7,32 . Multiple conditions with chronic disorders demonstrated loss of white and GM volume and tissue integrity 12,15,16,19,20,22 .…”

Effect of domiciliary oxygen therapy on exercise capacity and quality of life in patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomised, placebo-controlled trial

“…We have shown previously that cerebral tissue oxygenation is correlated to cognitive performance in PAH/ CTEPH patients [8], and that a lower cerebral tissue oxygenation during exercise is prevented with oxygen therapy [4,18]. Thus, by improving systemic and possibly cerebral oxygenation DOXT may have enhanced cerebral functions (table 3).…”

“…Mean nocturnal SpO 2 , oxygen desaturation index (ODI: number of SpO 2 dips ⩾4% lasting ⩾10 s•h −1 ), pulse rate and apnoea-hypopnoea index (AHI: number of apnoeas + hypopnoeas per hour with reduction of breathing amplitude <50% of baseline lasting ⩾10 s and associated with a SpO 2 dip ⩾4%) were determined [17]. Cognitive performance was tested using the Stroop test [18].…”

Identifying Nootropic Drug Targets via Large-Scale Cognitive GWAS and Transcriptomics

“…Earlier reports indicate that though PDE4C is expressed in the brain, limited to the cortex, thalamic nuclei and cerebellum 81 . No evidence currently exists to show if activating PDE4C plays a conclusive role in rescuing cognitive deficits 89 .…”